Evidence-led, with its limits made visible.
Migraine Club provides general education for people aged 16 and over. It does not diagnose migraine, recommend an individual treatment or claim that its content has clinical or regulatory approval.
Content version 1.3 · update review 25 October 2026 (cycle context and age suitability); core editorial review 12 August 2026
Review status
High-risk treatment, supplement, pregnancy and urgent-symptom wording was compared with current named sources. Language was kept general, uncertainty is stated, and individual decisions are directed to an appropriately qualified clinician or pharmacist. Review is brought forward for a material guidance change, safety alert or reported correction.
NICE — Headaches in over 12s: diagnosis and management (CG150)
Used for UK diagnosis context, acute treatment, prevention, medication-overuse, riboflavin and referral information.
Open NICE CG150NHS — Migraine
Used for patient-facing symptom, urgent-care, treatment, hydration, regular-meal, caffeine and alcohol context.
Open NHS MigraineInternational Headache Society — ICHD-3
Used for definitions and distinctions between migraine presentations. The app does not apply the criteria to make a diagnosis.
Open ICHD-3MHRA — Topiramate safety measures
Used for pregnancy and reproductive-safety wording for topiramate.
Open MHRA Drug Safety UpdateComfort practices and hard-day support
The Hard Day Support section separates established attack-care guidance from optional comfort practices. NHS migraine guidance supports rest in a darkened room during an attack, hydration, regular meals and regular exercise as general management. The app makes clear that movement during a severe attack may be intolerable and that resting is valid.
Topical magnesium, Epsom salts, scent, mentholated balms, massage, gua sha and acupressure are presented as personal comfort choices—not treatments proven to stop migraine. The in-app record includes a transdermal-magnesium evidence review and the US National Center for Complementary and Integrative Health peppermint-oil safety summary.
Open NCCIH peppermint-oil safety summaryAdditional evidence
The app’s detailed in-app record identifies further sources used for sleep/circadian context, behavioural approaches, let-down migraine, travel, supplements and transdermal magnesium. Source records include the version or check date and the precise way each source informed the copy.
Intended-purpose boundary
The app is positioned as personal record keeping and general education. Its charts and reports transparently summarise user-entered information and do not provide a diagnosis, attack prediction, medical risk score or personalised treatment decision. This position must be reassessed before adding any such feature.
Safety
Do not start, stop or change a medicine, supplement or device because of app content. Sudden severe headache, new weakness, speech difficulty, collapse, seizure, confusion, fever with neck stiffness or sudden vision loss needs urgent medical assessment.
App 1.1: hormonal context and ages 16–17
The cycle tab now explains the possible role of hormonal changes, with a separate source record and limits on interpretation. Patterns do not measure hormone levels, establish a cause or predict an attack. The app now includes ages 16–17. Treatment suitability differs by age: the app directs younger readers to a clinician or pharmacist and does not give them an individual treatment plan. The visible supplement-dose suggestion has been removed.
NICE CG150 covers young people from age 12 as well as adults; that scope does not make every treatment option suitable for every age. These edits are an editorial review, not independent clinical or regulatory approval.
Hormonal-cycle evidence
Observational studies cannot establish an individual cause. The small hormone-treatment trial is cited as research context, not a recommendation. The app does not infer hormone levels, fertility or an age-specific worsening point.